<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>7
<FILENAME>sinovacpressrel020304.txt
<DESCRIPTION>SINOVAC BIOTECH 6K, PRESS RELEASE 02.03.04
<TEXT>


EXHIBIT 99.4
------------



                              SINOVAC BIOTECH LTD.
             UPDATES FURTHER ON THE COMPLETION OF THE ACQUISITON OF
                 TANGSHAN YIAN BIOLOGICAL ENGINEERING CO., LTD.



BEIJING,  February 3, 2004 - Sinovac  Biotech  Ltd.  ("Sinovac")  (NASD  OTC-BB:
SNVBF;   Frankfurt:   SVQ)  wishes  to  further  update  the  January  30,  2004
announcement  of the  completion  of its  acquisition  of 100% of the issued and
outstanding shares of Tangshan Yian Biological  Engineering Co., Ltd. ("Tangshan
Yian" or "the Company").


Tangshan  Yian  operates in the city of  Tangshan,  People's  Republic of China.
Since  its  inception  in  1993,  the  Company  has  operated  as  an R & D  and
manufacturing  company  specializing  in the development  and  manufacturing  of
various vaccines  including flu, vaccines for Hepatitis A and Hepatitis A&B, and
a potential vaccine for SARS. Tangshan Yian supplies these vaccines to Sinovac's
subsidiary,  Sinovac  Biotech Co.,  Ltd.  The  operations  of Tangshan  Yian are
expected to supply  large-scale  quantities of new and updated  vaccines for the
domestic Chinese and international markets.


Tangshan Yian is located in the New Hi-tech  Development  Zone of Tangshan City,
connected by superhighways to Beijing, 150 kilometers to the east. The Company's
plant was built in accordance with the Pharmaceutical  Industrial  Standards and
Regulations  of China,  which are based on  international  standards.  The plant
itself is 4300 square  meters,  which includes a Biological  Safety  Laboratory,
Cell Culturing Workshop,  Pilot Trial Production Workshop,  Reagents Manufacture
Workshop,  and Research Lab for R&D of the Split Flu Vaccine.  Moreover,  within
the plant,  there is reserved space of about 1500 square  meters,  which will be
used as a vaccine manufacture  workshop.  The plant is situated on 20,000 square
meters  of land,  and has  reserved  an  additional  10,0000  square  meters  in
anticipation  of future  expansion.  The land is already  facilitated  with full
amenities.


Tangshan Yian provides Sinovac with a low-cost R & D and manufacturing base. The
cost of Tangshan  Yian's land is about 20% of its  equivalent  in Beijing  while
salaries  are  about  50% of those  paid to  equivalent  personnel  in  Beijing.
Furthermore,  the acquisition of Tangshan Yian contributes  talented  management
and scientists who will add significant  value to Sinovac's  progress in vaccine
development  and  manufacture.  These  favorable  attributes  are  even  further
compounded with the addition of Tanshan Yian's  state-of-the-art  facilities and
expanded manufacturing capabilities. These advantages could prove invaluable for
enhancing Sinovac's  competitive position in its progression towards large-scale
flu and potentially SARS vaccine manufacture.


Sinovac's  Beijing  operation  has  workshops  for  large-scale   production  of
inactivated  Hepatitis  A  vaccine  and  Hepatitis  A & B  combination  vaccine.
However,  according to GMP regulations  (government  regulated  standards called
Good Manufacturing Practices),  these workshops cannot be used for any other new
vaccine development. Therefore, the research and pilot production activities for
the flu vaccine and potential SARS vaccine  actually take place inside  Tangshan
Yian.


Sinovac's  potential  SARS vaccine has been approved for clinical  trials by the




<PAGE>






Chinese FDA (SFDA).  Tangshan Yian has produced  20,000 doses of this vaccine to
date and has the ability and  capacity to produce  more of the SARS  vaccine for
use in these  clinical  trials.  The  Company  will thus be able to  efficiently
produce  further  required  quantities  of the  vaccine  in  timely  manner.  Of
particular note is Tangshan Yian's  production-scaled  Biological Safety Level 3
laboratory,   which  includes  a  negative  pressure   facility.   These  highly
specialized,  so-called P3 labs, are necessary for research on highly infectious
and contagious  viruses and production of their associated  vaccines.  There are
only a few of these state-of-the-art labs in China.


Sinovac has conducted  clinical  trials on its flu vaccine.  In order to receive
further  approvals from the SFDA (Chinese Food and Drug  Administration),  a flu
vaccine  production  line must be built  and the  resulting  manufactured  final
product must meet SFDA standards. To achieve this production capability, Sinovac
is building a large-scale flu vaccine  production line at Tangshan Yian. Sinovac
is targeting to produce an initial  500,000 doses of flu vaccine for sale in the
flu season of 2004/5.  Actual production capacity is expected to be much greater
than this  quantity.  Market demand for a high quality but low-cost  inactivated
flu vaccine in China is certainly expected to number in the millions each year.


For further  information please refer to the Company's 6K filing with the SEC on
EDGAR or refer to Sinovac's website at http://www.sinovac.com/.
                                       -----------------------


Contact: Graham Taylor at (888) 888 8312 or (604) 684-5990.


MANAGEMENT  OF NET FORCE  WHO TAKE  FULL  RESPONSIBILITY  FOR ITS  CONTENTS  HAS
PREPARED  THIS NEWS  RELEASE.  THIS NEWS  RELEASE  MAY  INCLUDE  FORWARD-LOOKING
STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT
OF 1933,  AS  AMENDED,  AND  SECTION  21E OF THE UNITED  STATES  SECURITIES  AND
EXCHANGE  ACT  OF  1934,  AS  AMENDED,   WITH  RESPECT  TO  ACHIEVING  CORPORATE
OBJECTIVES,  DEVELOPING  ADDITIONAL PROJECT  INTERESTS,  NET FORCE'S ANALYSIS OF
OPPORTUNITIES  IN THE ACQUISITION  AND DEVELOPMENT OF VARIOUS PROJECT  INTERESTS
AND CERTAIN OTHER  MATTERS.  THESE  STATEMENTS  ARE MADE UNDER THE "SAFE HARBOR"
PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
AND INVOLVE RISKS AND  UNCERTAINTIES  WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER
MATERIALLY FROM THOSE IN THE FORWARD-LOOKING  STATEMENTS  CONTAINED HEREIN. THIS
NEWS RELEASE  SHALL NOT  CONSTITUTE AN OFFER TO SELL OR THE  SOLICITATION  OF AN
OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION
IN  WHICH  SUCH  OFFER,   SOLICITATION  OR  SALE  WOULD  BE  UNLAWFUL  PRIOR  TO
REGISTRATION   OR   QUALIFICATION   UNDER  THE  SECURITIES   LAWS  OF  ANY  SUCH
JURISDICTION.



</TEXT>
</DOCUMENT>
